Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Journey Medical CorporationNASDAQ: DERM
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $10.11M fell 4.4% year over year, ahead of the -24.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.
Context
- Selling, general & admin amounted to 71.7% of revenue in FY2025, up 0.1 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $50.24M (+13.2%) for the fiscal year ending Dec 2026, a step up from the +10.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.11M+2.5% QoQ
- Last fiscal yearDec 2025
- $44.37M+10.4% YoY
- LTMMar 2026
- $31.85M-24.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 44.37M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- +2.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.37M | +10.4% |
| FY2024 | 2024-12-31 | 40.2M | -8.4% |
| FY2023 | 2023-12-31 | 43.91M | -26.2% |
| FY2022 | 2022-12-31 | 59.47M | +49.3% |
| FY2021 | 2021-12-31 | 39.83M | — |
Selling, General & Admin vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.8% is the lowest of 10, against a peer median of +32.8%.
- Selling, general & admin amounts to 49.2% of revenue for DERM, versus a peer median of 102.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$92.98M CAD | +36.2% | — | 33.9% | |
| LTM Mar 2026 | $74.99M USD | -2.4% | -14.3% | 66.4% | |
| FY2025 | €53.89M EUR | +215.2% | +51.5% | 1202.1% | |
| LTM Mar 2026 | $52.43M USD | +32.8% | +31.8% | 102.8% | |
| LTM Mar 2026 | €51.66M EUR | +54.2% | +35.0% | 316.6% | |
| LTM Mar 2026 | $31.85M USD | -24.8% | -9.3% | 49.2% | |
| LTM Mar 2026 | $30.27M USD | +4.4% | +9.7% | 1705.2% | |
| LTM Mar 2026 | $26.99M USD | +11.1% | +24.6% | 82.5% | |
| LTM Mar 2026 | $25.32M USD | +141.6% | +29.5% | 264.1% | |
| LTM Mar 2026 | $14.41M USD | +9.9% | +10.3% | 99.5% | |
| Peer median (excluding DERM) | — | +32.8% | +27.1% | 102.8% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | 32.08M | 30.78M | 26.66M | 20.88M | 25.18M |
| Gross Profit | 31.05M | 42.89M | 52.52M | 35.26M | 36.68M |
| Gross Margin | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| Research & Development | 16.56M | 10.94M | 7.54M | 9.86M | 480K |
| Selling, General & Admin | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M |
| Operating Expenses | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.52M | 4.35M |
| EBITDA | (32.77M) | (23.18M) | 1.92M | (8.4M) | (3.33M) |
| EBITDA Margin | -51.9% | -31.5% | 2.4% | -15.0% | -5.4% |
| Operating Income | (34.88M) | (27.52M) | (2.07M) | (13.68M) | (8.17M) |
| Operating Margin | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Interest Income | 2K | 60K | 322K | 757K | 589K |
| Interest Expense | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M |
| Other Income / Expenses | (7.48M) | (2.05M) | (1.56M) | (934K) | (3.2M) |
| Income Before Tax | (42.36M) | (29.57M) | (3.63M) | (14.61M) | (11.37M) |
| Pre-Tax Margin | -67.1% | -40.1% | -4.6% | -26.0% | -18.4% |
| Income Tax Expense | 1.63M | 63K | 221K | 61K | 60K |
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Net Margin | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (Basic) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| EPS (Diluted) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| Weighted Avg Shares | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
| Weighted Avg Shares (Diluted) | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.